Status:

COMPLETED

Novel Biomarkers in Inflammatory Bowel Disease

Lead Sponsor:

Assiut University

Conditions:

Inflammatory Bowel Diseases

Eligibility:

All Genders

18-70 years

Brief Summary

The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing- inflammatory disorders of the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two major c...

Detailed Description

The inflammatory bowel diseases represent a heterogeneous group of chronic , relapsing-remitting inflammatory disorders of the gastrointestinal tract, and Crohn's disease and ulcerative colitis are am...

Eligibility Criteria

Inclusion

  • Newly diagnosed patients (untreated) by clinical and endoscopic examination and not received treatment .

Exclusion

  • patients have autoimmune diseases
  • patients with cancer

Key Trial Info

Start Date :

November 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 15 2021

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT03833310

Start Date

November 1 2019

End Date

April 15 2021

Last Update

January 7 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assuit Medical University

Asyut, Egypt

Novel Biomarkers in Inflammatory Bowel Disease | DecenTrialz